Our findings suggest that FGF21D2D3 is a more potent and effective protein than FGF21WT for treating DCM through improving dyslipidemia and directly inhibiting oxidative stress via FGFR1–AMPK activation in T2D. The gene discussed is FGFR1; the disease is familial dilated cardiomyopathy.